APPRECIATE (Apremilast Clinical Treatment Experience in Psoriasis): A Multi-center, Retrospective Observational Study of Real-World Experience of Psoriasis Patients Treated With Apremilast in Clinical Dermatology Practice
Phase of Trial: Phase IV
Latest Information Update: 05 Oct 2017
At a glance
- Drugs Apremilast (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Acronyms APPRECIATE
- Sponsors Celgene Corporation
- 23 Aug 2017 Planned number of patients changed from 475 to 515.
- 23 Aug 2017 Planned End Date changed from 1 May 2017 to 28 Feb 2018.
- 23 Aug 2017 Planned primary completion date changed from 1 May 2017 to 28 Feb 2018.